Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
Altern Ther Health Med ; 28(4): 40-43, 2022 May.
Article in English | MEDLINE | ID: covidwho-1876827


Despite the discovery of vaccines for COVID-19, one of the best security measures to contain the spread of the virus is social distancing and isolation. However, isolation might trigger negative mental outcomes, such as onset of a depressive and anxious condition, increased consumption of alcohol and drugs, relapse to substances of abuse, and even induce post-traumatic stress disorder. Interestingly, recent research with psychedelics suggests that when these substances are used in combination with psychotherapy, they may reduce these mental impairments. Nevertheless, scientists are still working to elucidate the possible mechanisms behind these phenomena.

COVID-19 Drug Treatment , Hallucinogens , COVID-19 Vaccines , Hallucinogens/pharmacology , Hallucinogens/therapeutic use , Humans , Mental Health , SARS-CoV-2
Ir J Psychol Med ; 38(2): 93-98, 2021 06.
Article in English | MEDLINE | ID: covidwho-722668


The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and maladaptive habitual patterns of cognition and behaviour, notably depression, addiction and obsessive compulsive disorder. The COMPASS Pathways (COMPASS) phase 2b double-blind trial of psilocybin therapy in antidepressant-free, treatment-resistant depression (TRD) is underway to determine the safety, efficacy and optimal dose of psilocybin. Results from the Imperial College London Psilodep-RCT comparing the efficacy and mechanisms of action of psilocybin therapy to the selective serotonin reuptake inhibitor (SSRI) escitalopram will soon be published. However, the efficacy and safety of psilocybin therapy in conjunction with SSRIs in TRD is not yet known. An additional COMPASS study, with a centre in Dublin, will begin to address this question, with potential implications for the future delivery of psilocybin therapy. While at a relatively early stage of clinical development, and notwithstanding the immense challenges of COVID-19, psilocybin therapy has the potential to play an important therapeutic role for various psychiatric disorders in post-COVID-19 clinical psychiatry.

COVID-19 , Hallucinogens , Psychiatry , Hallucinogens/therapeutic use , Humans , Psilocybin/therapeutic use , SARS-CoV-2